- Home
- MOB vs RLMD Comparison
MOB vs RLMD Comparison
Compare MOB & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOB
- RLMD
- Stock Information
- Founded
- MOB 2008
- RLMD 2004
- Country
- MOB Israel
- RLMD United States
- Employees
- MOB N/A
- RLMD N/A
- Industry
- MOB Real Estate Investment Trusts
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- MOB Real Estate
- RLMD Health Care
- Exchange
- MOB Nasdaq
- RLMD Nasdaq
- Market Cap
- MOB 18.0M
- RLMD 11.5M
- IPO Year
- MOB 2022
- RLMD N/A
- Fundamental
- Price
- MOB $2.50
- RLMD $0.34
- Analyst Decision
- MOB
- RLMD Hold
- Analyst Count
- MOB 0
- RLMD 4
- Target Price
- MOB N/A
- RLMD $4.25
- AVG Volume (30 Days)
- MOB 440.5K
- RLMD 481.7K
- Earning Date
- MOB 03-25-2025
- RLMD 03-18-2025
- Dividend Yield
- MOB N/A
- RLMD N/A
- EPS Growth
- MOB N/A
- RLMD N/A
- EPS
- MOB N/A
- RLMD N/A
- Revenue
- MOB $3,464,353.00
- RLMD N/A
- Revenue This Year
- MOB N/A
- RLMD N/A
- Revenue Next Year
- MOB N/A
- RLMD N/A
- P/E Ratio
- MOB N/A
- RLMD N/A
- Revenue Growth
- MOB 169.70
- RLMD N/A
- 52 Week Low
- MOB $0.71
- RLMD $0.32
- 52 Week High
- MOB $5.00
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- MOB 40.80
- RLMD 25.71
- Support Level
- MOB $2.67
- RLMD $0.34
- Resistance Level
- MOB $3.13
- RLMD $0.38
- Average True Range (ATR)
- MOB 0.34
- RLMD 0.03
- MACD
- MOB -0.10
- RLMD 0.04
- Stochastic Oscillator
- MOB 14.06
- RLMD 21.01
About MOB Mobilicom Limited
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.